SCHEMBL1879545

SCHEMBL1879545

Cc1cccc(-c2noc(N)c2-c2ccncn2)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.54
MAPK9 P45984 2/20 0.54
MAPK10 P53779 1/20 0.54
MAPK11 Q15759 1/20 0.54
LMNA P02545 1/20 0.39
NUDT1 P36639 3/20 0.37
EDNRA P25101 1/20 0.36
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PRKDC P78527 1/20 0.34
BRD4 O60885 1/20 0.33
TDO2 P48775 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CYP17A1 P05093 2/20 0.33
CDC7 O00311 1/20 0.33
PLK4 O00444 1/20 0.33
MAPK13 O15264 1/20 0.33
PDPK1 O15530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1877430 0.90 MAPK14 (0.56) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1874520 0.88 MAPK14 (0.60) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL4334926 0.83 MAPK14 (0.52) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1877244 0.81 MAPK14 (0.55) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1883835 0.80 MAPK14 (0.61) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1876450 0.80 MAPK14 (0.54) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1877688 0.79 MAPK14 (0.56) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1880930 0.79 MAPK14 (0.56) MAPK14MAPK9MAPK10MAPK11LMNA
SCHEMBL1873514 0.78 MAPK14 (0.53) MAPK14MAPK9MAPK10MAPK11PIK3CD
SCHEMBL27732755 0.77 NUDT1 (0.40) MAPK9LMNANUDT1EDNRAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.